An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Key Inclusion Criteria: * Patients had to have participated in the core study CAIN457F2304 and completed the entire treatment period up to and including Week 104. * Patients had to be deemed by the investigator to benefit from continued secukinumab therapy. Key Exclusion Criteria: * Patients with plans for administration of live vaccines during the extension study period were excluded. * Patients taking any other concomitant biologic immunomodulating agent(s) except secukinumab were excluded. * Patients who were deemed not to be benefiting from the study treatment based on lack of improvement or worsening of their symptoms were excluded.